These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
229 related articles for article (PubMed ID: 12975664)
1. [Summary of our clinical experience with the determination of serum prostate-specific antigen level in the first five years]. Bánfi G; Kiss F; Kádár A; Romics I Magy Onkol; 2003; 47(2):165-8. PubMed ID: 12975664 [TBL] [Abstract][Full Text] [Related]
2. [Prostate-specific antigen as a tumor marker of prostate carcinoma]. Wymenga LF; Mensink HJ Ned Tijdschr Geneeskd; 1999 Aug; 143(34):1733-8. PubMed ID: 10494319 [TBL] [Abstract][Full Text] [Related]
3. [The evaluation of the ratio of free and total serum prostate-specific antigen as an additional method in the diagnosis of prostatic cancer]. Reznikov IuP; Mazanov GP; Sedova TN Urol Nefrol (Mosk); 1996; (6):41-3. PubMed ID: 9036610 [TBL] [Abstract][Full Text] [Related]
4. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM). Roobol MJ; Kranse R; de Koning HJ; Schröder FH Urology; 2004 Feb; 63(2):309-13; discussion 313-5. PubMed ID: 14972478 [TBL] [Abstract][Full Text] [Related]
5. Do changes in a high serum prostate-specific antigen level and the free/total prostate-specific antigen ratio after antibiotic treatment rule out biopsy and the suspicion of cancer? Dirim A; Tekin MI; Koyluoglu E; Oguzulgen AI; Peskircioglu L; Ozkardes H Urol Int; 2009; 82(3):266-9. PubMed ID: 19440011 [TBL] [Abstract][Full Text] [Related]
6. Role of AgNOR count and its correlation with serum PSA levels in prostatic lesions. Goel T; Garg S Urol Int; 2009; 82(3):286-90. PubMed ID: 19440015 [TBL] [Abstract][Full Text] [Related]
7. [Prostate-specific antigen (PSA): diagnostic and prognostic implications in the evaluation of carcinoma of the prostate]. Lo Cigno M; Montanari F; Bercovich E; Soli M; Emili E; Dal Pozzo C; Platè L; Bianchi D Arch Ital Urol Nefrol Androl; 1989 Mar; 61(1):29-36. PubMed ID: 2469127 [TBL] [Abstract][Full Text] [Related]
8. [Tumor markers in prostate cancer]. Kuriyama M Gan To Kagaku Ryoho; 1994 Sep; 21(12):1915-22. PubMed ID: 7521999 [TBL] [Abstract][Full Text] [Related]
9. Prostatic volume and volume-adjusted prostate-specific antigen as predictive parameters for T1c prostate cancer. Tanaka N; Fujimoto K; Yoshikawa M; Tanaka M; Hirao Y; Kondo H; Saito I Hinyokika Kiyo; 2007 Jul; 53(7):459-65. PubMed ID: 17702178 [TBL] [Abstract][Full Text] [Related]
10. [Staging of prostate cancer: value of the combined information of endorectal MRI, biopsy Gleason score, and preoperative PSA level]. Wetter A; Ajdukovic AN; Fliessbach K; Lehnert T; Engl T; Jacobi V; Vogl TJ Rofo; 2006 Apr; 178(4):385-90. PubMed ID: 16607587 [TBL] [Abstract][Full Text] [Related]
11. Prostate carcinoma detection and increased prostate-specific antigen levels after 4 years in Dutch and Japanese males who had no evidence of disease at initial screening. Ito K; Raaijmakers R; Roobol M; Wildhagen M; Yamanaka H; Schröder FH Cancer; 2005 Jan; 103(2):242-50. PubMed ID: 15578715 [TBL] [Abstract][Full Text] [Related]
12. Clinical usefulness of serum antip53 antibodies for prostate cancer detection: a comparative study with prostate specific antigen parameters. Suzuki H; Akakura K; Igarashi T; Ueda T; Ito H; Watanabe M; Nomura F; Ochiai T; Shimada H J Urol; 2004 Jan; 171(1):182-6. PubMed ID: 14665872 [TBL] [Abstract][Full Text] [Related]
13. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging. Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354 [TBL] [Abstract][Full Text] [Related]
14. The effect of antibiotics on elevated serum prostate specific antigen in patients with urinary symptoms and negative digital rectal examination: a pilot study. Bulbul MA; Wazzan W; Hijaz A; Shaar A J Med Liban; 2002; 50(1-2):23-5. PubMed ID: 12841309 [TBL] [Abstract][Full Text] [Related]
15. Prevalence of prostate cancer at different levels of serum prostate-specific antigen (PSA) and different free: total PSA ratios in a consecutive series of men referred for prostate biopsies. Rydén L; Egevad L; Ekman P; Hellström M Scand J Urol Nephrol; 2007; 41(4):302-7. PubMed ID: 17763221 [TBL] [Abstract][Full Text] [Related]
16. Circulating tumour-associated plasma DNA represents an independent and informative predictor of prostate cancer. Chun FK; Müller I; Lange I; Friedrich MG; Erbersdobler A; Karakiewicz PI; Graefen M; Pantel K; Huland H; Schwarzenbach H BJU Int; 2006 Sep; 98(3):544-8. PubMed ID: 16925751 [TBL] [Abstract][Full Text] [Related]
17. [Value of prostate specific antigen in early diagnosis of prostatic cancer]. Xiao LP; Bi XJ; Li YN; Chen XQ; Zhang XF; Yu XP; Liu G; Yang MC; Song Z Nan Fang Yi Ke Da Xue Xue Bao; 2007 Jan; 27(1):107-8, 112. PubMed ID: 17259162 [TBL] [Abstract][Full Text] [Related]
18. [The usefulness of prostate-specific antigen assay for the early detection and follow up of the prostate cancer]. Saito Y Nihon Rinsho; 1998 Aug; 56(8):1989-93. PubMed ID: 9750493 [TBL] [Abstract][Full Text] [Related]
19. [Prostate specific antigen: a role of PSA in the diagnosis of prostate cancer]. Nutahara K; Higashihara E Rinsho Byori; 2001 Oct; 49(10):963-6. PubMed ID: 11769472 [TBL] [Abstract][Full Text] [Related]
20. [Prostate specific antigen and diagnosis of prostate cancer]. Rigaud J; Bouchot O Rev Prat; 2003 Dec; 53(20):2229-36. PubMed ID: 15018076 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]